The Lost Lessons of the Pandemic
By all accounts, COVID-19 has ebbed: the vaccines worked, and herd immunity has been attained in some countries. But the spread of a new subvariant underscores how the failure to reform an unjust innovation governance regime has prevented policymakers from harnessing pharmaceutical advances for the benefit of all.
WATERLOO, CANADA – The rituals of fall in the northern hemisphere now include preparing for a fresh variant of COVID-19, in addition to the annual flu season. This year, it is EG.5 (nicknamed Eris, the ancient Greek goddess of strife and discord), a subvariant of Omicron that is already prevalent in the United States, Canada, and several Asian countries.